Questcor Pharmaceuticals — JP Morgan 2013 Healthcare Conference
26 slides from Questcor Pharmaceuticals's conference presentation, Jan 9, 2013

Slide 1: JP Morgan 2013 Healthcare Conference
January 2013 NASDAQ: QCOR January 2013 NASDAQ: QCOR JP Morgan 2013 Healthcare Conference Steve Cartt Chief Operating Officer Exhibit 99.1

Slide 2: Safe Harbor Statement
Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc

Slide 3: A biopharmaceutical company focused on serious autoimmune and inflammatory disorders
A biopharmaceutical company focused on the treatment of patients with serious, difficult-to- treat autoimmune and inflammatory disorders Questcor 3 A biopharmaceutical company focused on the treatment of patients with serious, difficult-to- treat autoimmune and inflammatory disorders

Slide 4: Questcor Overview
Flagship Product: • Profitable, positive cash flow, strong balance sheet • 19 approved indications Key Therapeutic Areas: • Nephrotic Syndrome, Multiple Sclerosis Relapse, Infantile Spasms, Dermatomyositis/Polymyositis • Significant areas of unmet need; large growth potential Strategy: • Expand awar

Slide 5: Approved Acthar Indications Provide Strong Growth Potential
19 Approved Acthar Indications Provide Strong Growth Potential 5 Nephrotic Syndrome (NS) (2 Indications) Multiple Sclerosis Relapses (MS) Infantile Spasms (IS) Rheumatology-Related Conditions ( 6 Indications) Key Indications:

Slide 6: Acthar Usage Expanding Rapidly
Acthar Usage Expanding Rapidly 6 Vials per Quarter 6,000 5,000 4,000 3,000 2,000 1,000

Slide 7: Strong Net Sales Growth
Strong Net Sales Growth 7 Net Sales per Quarter -

Slide 8: Estimated Allocation of Acthar Net Sales
Estimated Allocation of Acthar Net Sales 8 Note: Questcor sells Acthar to a distributor and does not have complete data with respect to end-use; allocation based on internal estimates (Q3 2012). Infantile Spasms ~9% Other ~3% Syndrome 45-47% MS Relapse 40-44% Nephrotic

Slide 9: Stable Reimbursement Environment
• MDs typically reserve Acthar for when another FDA- approved treatment alternative is needed, usually after first-line therapy – Serious, difficult-to-treat medical conditions • Coverage decisions are determined on a case-by-case basis, considering patient condition, disease severity, and treatment

Slide 10: Increasing Support of Questcor-Sponsored and Independent Research Projects
Increasing Support of Questcor-Sponsored and Independent Research Projects 10 R&D Spending Clinical & Preclinical Studies 2007 2008 2009 2010 2011 9m 2012 2007 2008 2009 2010 2011 9m 2012 22.1 16.8 10.9 9.7 10.6 4.8

Slide 11: Nephrotic Syndrome (NS)
Nephrotic Syndrome (NS) Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) Caused by a number of underlying types of kidney disease (eg, iMN, FSGS, IgA nephropathy, etc.) Can result in end-stage renal disease (ESRD), dialysis, transplant Significant unmet ne

Slide 12: Multiple Sclerosis (MS) Relapse
Multiple Sclerosis (MS) Relapse 12 Lublin et al. Neurology • • • Relapses can range from mild to severe, and can cause a range of symptoms, from loss of sensation in the extremities, to loss of vision and the ability to walk Research indicates that relapses have a measurable and sustained effect on

Slide 13: Infantile Spasms (IS)
• Devastating, ultra-rare form of childhood epilepsy • Can cause permanent developmental disabilities, increased mortality • Acthar is often considered the “gold standard” and is currently used to treat 40-50% of IS patients Infantile Spasms (IS) 13 • Devastating, ultra-rare form of childhood epilep

Slide 14: Rheumatology
4 key indications on the Acthar label* – Dermatomyositis/Polymyositis (DM/PM) – Systemic lupus erythematosus (Lupus) – Psoriatic arthritis – Rheumatoid arthritis Each can pose a serious health risk if not adequately controlled Some cases difficult to manage; Acthar is an FDA- approved treatment alte

Slide 15: How Does Acthar Work?
How Does Acthar Work? Treats autoimmune conditions across a variety of organ systems Appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors Activity extends beyond steroidogenesis – Acthar binds to all 5 melanocortin receptors (MC1R-5R) f

Slide 16: Acthar Binds to Melanocortin Receptors
Receptor Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Acthar Binds to Melanocortin Receptors 16 MC1R Podocytes, Renal Mesangial Cells, Endothelial Cells, Tubular Epithelial Cells, Macrophages, Melanocytes, Immune/Inflammatory Cells, Kerantinocytes, CNS MC2R

Slide 17: Understanding The Science Behind Acthar
• Grow the body of Acthar evidence for on-label indications • Examples of ongoing projects: lupus, dermatomyositis/polymyositis, idiopathic membranous nephropathy • Better understand the biological properties of Acthar Specific biochemical pathways, cells, and tissues Immunomodulation and anti-infla

Slide 18: Biosimilar Pathways Highly Challenging
• Complex formulation and pharmacology, with multiple receptor binding properties – Slow release gel formulation – Complex and not well characterized (research is ongoing) • Formulation and manufacturing trade secrets inherent with Acthar • Synthetic competitor may be possible, but in specific indic

Slide 19: Financial Trends
Financial Trends 19 Net Sales EPS 2008 2009 2010 2011 2012 9m 2008 2009 2010 2011 2012 9m $2.50 $2.00 $1.50 $1.00 $0.50 $0.00 0.49 0.40 0.54 1.21 2.12

Slide 20: Financial Trends
20 Financial Trends Cash Flow from Operations ROE 2007 2008 2009 2010 2011 2012 9m 2008 2009 2010 2011 2012 9m 110% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

Slide 21: Q3-2012 Financial Results
Q3-2012 Financial Results 21 Q3 – 2012 Q3 – 2011 Record Net Sales (up 135%) and EPS (up 160%) Net Sales ($M) Gross Profit ($M) Operating Income ($M) Fully Diluted, GAAP EPS Cash flow from operations (YTD $M) Diluted shares outstanding $140.3 $132.8 $83.4 $0.91 $135 61.4 $59.8 $56.1 $33.6 $0.35 $54 6

Slide 22: Committed to Creating Long Term Value for Shareholders
• Identifying and expanding Acthar therapeutic role in existing and new indications • Long term investment in R&D -- doubled R&D spending YOY • Highly selective, strategic diversification • Have already returned $322 million to shareholders through share repurchases – 21.4 million shares repurchased

Slide 23: Strategic Acquisition: BioVectra Inc.
• Questcor Pharmaceuticals Acquiring BioVectra Inc. – Acthar Active Pharmaceutical Ingredient (API) manufacturer • Further secures Acthar ® API supply and manufacturing trade secrets • Provides Questcor with third party manufacturing capabilities • Expected to be accretive to future financial result

Slide 24: Acthar: A Sustainable Engine for Growth
Acthar: A Sustainable Engine for Growth 24 Five Year Plan • Continue to expand usage in MS relapse, NS indications • Build and expand usage in Rheumatology indications • Continue to serve IS patient population and child neurologists • Evaluate therapeutic potential in other remaining on-label indica

Slide 25: Investment Highlights
Investment Highlights 25 Acthar has a unique therapeutic role and sustainable competitive advantages Acthar is approved for 19 indications, many in markets with sizable unmet need Sales in NS and MS have increased, yet market penetration remains modest Questcor is increasingly capable of funding sig

Slide 26: January 2013
NASDAQ: QCOR NASDAQ: QCOR January 2013
Source: SEC EDGAR · 8-K filed Jan 9, 2013
More decks from Questcor Pharmaceuticals Inc
FY2013 Earnings Presentation19 slides · Mar 3, 2014
J.P. Morgan Healthcare Conference 201444 slides · Jan 13, 2014
Oppenheimer Healthcare Conference 201337 slides · Dec 11, 2013
Q3 2013 Earnings Presentation17 slides · Nov 4, 2013
Q2 2013 Earnings Presentation14 slides · Aug 6, 2013
Investor Presentation (August 2013)29 slides · Aug 6, 2013